

Remarks

The claims have been amended to recite that A is furan. Support for this amendment can be found, for example, in paragraph [0017] of the application as filed as well as the compounds in the table following paragraph [0026] of the application as filed.

The claims have also been amended to recite that Y is S, -S(O)-, or -S(O)₂-, consistent with the restriction requirement.

The definition of R₁ in the claims has been amended by removing -H.

Claims 1, 2, and 11 were provisionally rejected for obviousness-type double patenting over claims 24, 25, and 27 of co-pending application 10/975,761. These claims recite compounds in which A is benzimidazole. With the amendment defining A as furan presented hereinabove, the applicants respectfully submit that this rejection is obviated and respectfully request its reconsideration and withdrawal.

Claims 1, 2, and 11 were rejected as anticipated by US 5,554,767. With the amendment removing -H from the definition of R₁ presented hereinabove, applicants respectfully submit that this rejection is obviated and request its reconsideration and withdrawal.

Claim 11 was objected to for reciting a compound but including the phrase "together with a pharmaceutically acceptable carrier, executed, or diluent." Claim 11 has been amended to recite a composition, thereby obviating this objection.

If it is believed that a teleconference will advance prosecution, the examiner is encouraged to contact the undersigned as indicated below.

Date: December 3, 2008

Telephone: 312-913-0001
Facsimile: 312-913-0002

Respectfully submitted,

/Michael S. Greenfield/
Michael S. Greenfield
Registration No. 37,142

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive
Chicago, IL 60606